- Home
- AGL vs CYCN Comparison
AGL vs CYCN Comparison
Compare AGL & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | CYCN |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AGL | CYCN |
|---|---|---|
| Price | $27.21 | $3.33 |
| Analyst Decision | Hold | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $55.68 | N/A |
| AVG Volume (30 Days) | 403.5K | ★ 8.3M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $5,932,576,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.23 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.30 | $1.03 |
| 52 Week High | $32.36 | $8.48 |
Technical Indicators
Market Signals| Indicator | AGL | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 69.94 | 58.02 |
| Support Level | $0.63 | $1.23 |
| Resistance Level | $32.36 | $3.76 |
| Average True Range (ATR) | 3.83 | 0.26 |
| MACD | -0.37 | -0.06 |
| Stochastic Oscillator | 66.86 | 74.30 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.